Skip to main content

Definium Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

DFTX$34.64-2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney (included on signature page hereto)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Rob Barrow and Brandi L. Roberts as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and substitution, for him or her and in his or her name, place, and stead, in any and all capacities (including his/her capacity as a director and/or officer of Definium Therapeutics, Inc.) to sign any or all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents or any of them, or their, his, or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Robert BarrowChief Executive Officer and DirectorFebruary 26, 2026
Robert Barrow(Principal Executive Officer)
/s/ Brandi L. RobertsChief Financial OfficerFebruary 26, 2026
Brandi L. Roberts(Principal Financial Officer and Principal Accounting Officer)
/s/ Carol ValloneDirectorFebruary 26, 2026
Carol Vallone
/s/ David GryskaDirectorFebruary 26, 2026
David Gryska
/s/ Roger CrystalDirectorFebruary 26, 2026
Roger Crystal, MD
/s/ Andreas KrebsDirectorFebruary 26, 2026
Andreas Krebs
/s/ Roger AdsettDirectorFebruary 26, 2026
Roger Adsett
/s/ Suzanne BruhnDirectorFebruary 26, 2026
Suzanne Bruhn, PhD
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.